Global Non-oncology Biopharmaceuticals Market - 2021-2028

Global Non-oncology Biopharmaceuticals Market - 2021-2028

Market Overview

The global non-oncology biopharmaceuticals market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Biopharmaceuticals are part of the wider category of therapeutic agents called biologics. Biopharmaceuticals are substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs used to treat various diseases rather than cancer, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Market Dynamics

The global non-oncology biopharmaceuticals market growth is driven by the increasing launches, approvals, robust pipeline of novel biopharmaceuticals, increasing mergers and collaborations among key players.

Increasing launches, approvals, robust pipeline of novel biopharmaceuticals is expected to drive the growth in the forecast period

Frequent approvals, launches, and a robust pipeline of novel non-oncology biopharmaceuticals for various indications in the market are expected to support the U.S. non-oncology biopharmaceutical's market growth significantly. For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection to prevent migraine in adults.

In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.

High price of branded biologic products is likely to hinder the market growth

According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.

COVID-19 Impact Analysis

With the outbreak of COVID-19, the healthcare sector is adopting new technology that can help hospitals overcome the current pandemic and future medical emergencies. Owing to the growing adoption of new tools and technologies, the global biopharmaceutical fermentation systems market is projected to grow substantially during the coming years. COVID-19 has become a global pandemic and consumed more than a million lives. This has stimulated healthcare companies are developing innovative tools and technologies that can help doctors and medical officers to overcome present and future medical emergencies. For instance, In February 2021, Rentschler Biopharma; a Germany-based contract development and manufacturing organization (CDMO) announced to start commercial manufacture, formulation, and downstream processing of CVnCoV COVID-19 candidate vaccine by CureVac. Similarly, Bayer also announced to manufacture 160 million doses of CVnCoV in 2022. Owing to this, the global biopharmaceutical fermentation systems market is projected to grow exponentially in the coming years.

Segment Analysis

The biologics segment is expected to hold the largest share in this market segment

Biologic drugs are used in the treatment of major chronic diseases like autoimmune diseases, which has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019, three biological drugs were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffons.

There are also increasing investments that have helped in driving the overall market growth. Novartis AG invested around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility which was expected to be completed by 2019.

Furthermore, biologics prove efficient in treating rheumatoid arthritis and Crohn’s disease, which boosts the market even further.

Geographical Analysis

North America region holds the largest market share of global non-oncology biopharmaceuticals market

North American market has dominated the global non-oncology biopharmaceuticals market, and it is estimated to show a similar trend during the forecast period. The primary factors driving the market are the increasing incidences of chronic diseases, well-established pharmaceutical companies, and an increase in biotech companies.

With the rising COVID-19 pandemic, US-based companies are racing to develop vaccines against COVID-19. For instance, in March 2020, a Phase 1 clinical trial began at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle to evaluate an investigational vaccine designed to protect against COVID-19. The vaccine is being developed by NIAID scientists and their collaborators at the biotechnology company Moderna Inc.

For instance, in August 2020, Biocon Biologics India, a fully integrated biosimilars company and a subsidiary of Biocon Ltd, and Mylan NV announced the US launch of Semglee (insulin glargine injection). Hence, all these factors are found to boost the overall market growth in the region.

Competitive Landscape

The global non-oncology biopharmaceuticals market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Eli Lilly and Company, GlaxoSmithKline, Novartis, Amgen Inc, AbbVie Inc, AstraZeneca, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Elusys Therapeutics and Swedish Orphan Biovitrum. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, Leadiant Biosciences, Inc. got FDA approval for its Revcov (elapegademase-lvlr) injection in the United States in October 2018. Revcovi is a new enzyme replacement therapy (ERT) for pediatric and adult patients with adenosine deaminize severe combination immune deficiency (ADA-SCID).

Global Non-oncology Biopharmaceuticals Market – Key Companies to Watch

Novartis AG

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland established in 1996. It operates business through two divisions: Innovative medicine, Sandoz, made up of two business units – Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology.

Product Portfolio: It includes product like Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older.

Why Purchase the Report?
• Visualize the composition of the non-oncology biopharmaceuticals market segmentation by product type, application, and region highlighting the key commercial assets and players.
• Identify commercial opportunities in non-oncology biopharmaceuticals market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of non-oncology biopharmaceuticals market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players.

The global non-oncology biopharmaceuticals market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Market Segmentation

Global Non-oncology Biopharmaceuticals Market – By Product Type
• Biologics
• Biosimilars

Global Non-oncology Biopharmaceuticals Market – By Application
• Immunology
• Endocrinology
• Others

Global Non-oncology Biopharmaceuticals Market - By Region
• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• South America